,Keyword_1,frequency,Keyword_2,degreee
0,rnai,42,rnai,168
1,rna interference,29,sirna,104
2,sirna,24,rna interference,96
3,gene therapy,19,gene therapy,70
4,cancer therapy,9,shrna,34
5,shrna,8,cancer,32
6,gene silencing,7,cancer therapy,27
7,cancer,7,therapy,27
8,delivery,7,delivery,26
9,therapy,6,hiv-1,24
10,hiv-1,6,gene silencing,22
11,nanoparticles,4,atelocollagen,19
12,microrna,4,nanoparticles,17
13,atelocollagen,4,liposome,15
14,mirna,3,mirna,14
15,gene,3,microrna,14
16,sirna delivery,3,antiviral,14
17,short interfering rna (sirna),3,gene,12
18,systemic delivery,3,sirna delivery,12
19,liposome,3,systemic delivery,12
20,small interfering rna,3,small interfering rna,10
21,antiviral,3,allergy,10
22,rna interference (rnai),3,off-target effect,9
23,drug delivery,2,viral escape,9
24,nanocarriers,2,nanocarriers,8
25,targeted,2,tumor,8
26,tumor,2,neurodegenerative,8
27,rnai therapeutics,2,rna,8
28,off-target effect,2,targeted,7
29,neurodegenerative,2,rnai therapeutics,7
30,allergy,2,short interfering rna (sirna),7
31,short hairpin rna,2,inflammation,7
32,inflammation,2,rheumatoid arthritis,7
33,rheumatoid arthritis,2,neurodegenerative diseases,7
34,micrornas,2,rna interference (rnai),7
35,viral escape,2,ptgs,7
36,neurodegenerative diseases,2,drug delivery,6
37,rna,2,plk-1,6
38,ptgs,2,dds,6
39,dna nanotechnology,1,short hairpin rna,6
40,multidrug resistance,1,micrornas,6
41,cancer hallmarks,1,molecular imaging,5
42,iron oxide nanoparticles,1,nanocarrier,5
43,mri,1,cancer therapeutics,5
44,tumor penetration,1,kras,5
45,lung cancer,1,myc,5
46,biomarkers,1,sirnas,5
47,rnai-based therapy,1,synthetic lethality,5
48,huntington's disease,1,asthma,5
49,off-target effects,1,bacteria-mediated rnai,5
50,glioblastoma,1,bm-rnai,5
51,gbm,1,lipid,5
52,mouse models,1,endosome,5
53,lipid nanoparticles,1,hcv,5
54,exosomes,1,liver disease,5
55,extracellular vesicles,1,virus evolution,5
56,antithrombotic therapy,1,combination,5
57,thrombosis,1,respiratory viruses,5
58,pharmacology,1,transcription factor,5
59,near-infrared light response,1,drug discovery,5
60,swnt,1,conserved target sequences,5
61,hsp70b' promoter,1,h5n1,5
62,kidney stone,1,influenza,5
63,nephrolithiasis,1,pandemic flu,5
64,primary,1,rna silencing,5
65,molecular imaging,1,suppressors,5
66,nanocarrier,1,ebola virus,5
67,host-directed therapy,1,influenza a virus,5
68,inhalation,1,resistance,5
69,non-viral vectors,1,escape,5
70,ph-responsive,1,cancer hallmarks,4
71,cancer therapeutics,1,iron oxide nanoparticles,4
72,kras,1,mri,4
73,myc,1,tumor penetration,4
74,sirnas,1,huntington's disease,4
75,synthetic lethality,1,off-target effects,4
76,clinical trials,1,glioblastoma,4
77,dsirna,1,gbm,4
78,long qt syndrome,1,mouse models,4
79,dominant-negative suppression,1,kidney stone,4
80,self-assembled nanoparticle,1,nephrolithiasis,4
81,tumor-homing and penetrating,1,primary,4
82,ingr,1,ph-responsive,4
83,leukemia,1,clinical trials,4
84,molecular therapy,1,dsirna,4
85,nonviral vectors,1,barriers,4
86,delivery vehicle,1,clinical,4
87,pharmaceutical companies,1,antiviral therapy,4
88,nanotechnology,1,animal virus,4
89,synthase,1,nanomedicine,4
90,hepatitis-c virus,1,oncogene addiction,4
91,aptamer-sirna chimeras,1,rnai delivery,4
92,barriers,1,delivery vectors,4
93,clinical,1,hbv,4
94,update,1,leukocytes,4
95,antiviral therapy,1,integrins,4
96,animal virus,1,liposomes,4
97,multidrug resistant microorganism,1,disease,4
98,nanoantibiotics,1,research,4
99,gastric cancer,1,therapeutics,4
100,inhibiting effect,1,delivery systems,4
101,nanomedicine,1,nanoparticle,4
102,oncogene addiction,1,molecular,4
103,rnai delivery,1,huntington's,4
104,pdx1,1,alzheimer's,4
105,pancreatic cancer,1,hiv,4
106,delivery vectors,1,targeted delivery,4
107,hbv,1,t-cell,4
108,leukocytes,1,in vivo delivery,4
109,integrins,1,duration,4
110,liposomes,1,side effect,4
111,cell death,1,hydrodynamic,4
112,cell survival,1,heart failure,4
113,in vivo,1,hypertrophy,4
114,disease,1,lentiviral vector,4
115,research,1,neurons,4
116,therapeutics,1,rnai therapy,4
117,delivery systems,1,preclinical application,4
118,nanoparticle,1,cns,4
119,molecular,1,rnai delivery systems,4
120,cationic lipid,1,biotherapy,4
121,adenovirus,1,tnf,4
122,helper-dependent adenovirus,1,dicer inhibition,4
123,hepatitis b virus,1,dna nanotechnology,3
124,hepatitis c,1,multidrug resistance,3
125,chemical stability,1,lung cancer,3
126,gene expression,1,biomarkers,3
127,autoimmune,1,rnai-based therapy,3
128,angiogenesis,1,lipid nanoparticles,3
129,endothelial dysfunction,1,exosomes,3
130,atu027,1,extracellular vesicles,3
131,huntington's,1,near-infrared light response,3
132,alzheimer's,1,swnt,3
133,plk-1,1,hsp70b' promoter,3
134,dds,1,host-directed therapy,3
135,metastasis,1,inhalation,3
136,non-hodgkins-lymphoma,1,non-viral vectors,3
137,toll-like receptor-3,1,long qt syndrome,3
138,asthma,1,dominant-negative suppression,3
139,bacteria-mediated rnai,1,self-assembled nanoparticle,3
140,bm-rnai,1,tumor-homing and penetrating,3
141,hiv,1,ingr,3
142,targeted delivery,1,leukemia,3
143,t-cell,1,molecular therapy,3
144,lipid,1,nonviral vectors,3
145,endosome,1,delivery vehicle,3
146,in vivo delivery,1,pharmaceutical companies,3
147,duration,1,nanotechnology,3
148,side effect,1,update,3
149,hydrodynamic,1,gastric cancer,3
150,conditional rnai,1,inhibiting effect,3
151,inducible rnai,1,cell death,3
152,transgenic rnai,1,cell survival,3
153,cre/loxp,1,cationic lipid,3
154,hcv,1,adenovirus,3
155,liver disease,1,helper-dependent adenovirus,3
156,heart failure,1,hepatitis b virus,3
157,hypertrophy,1,hepatitis c,3
158,lentiviral vector,1,chemical stability,3
159,neurons,1,gene expression,3
160,rnai therapy,1,autoimmune,3
161,preclinical application,1,angiogenesis,3
162,virus evolution,1,endothelial dysfunction,3
163,combination,1,atu027,3
164,cns,1,conditional rnai,3
165,rnai delivery systems,1,inducible rnai,3
166,respiratory viruses,1,transgenic rnai,3
167,transcription factor,1,cre/loxp,3
168,drug discovery,1,virus,3
169,conserved target sequences,1,evading,3
170,h5n1,1,strategies,3
171,influenza,1,gene delivery,3
172,pandemic flu,1,therapeutic rnai,3
173,rna silencing,1,polyglutamine,3
174,suppressors,1,huntington disease,3
175,ebola virus,1,darpp-32,3
176,influenza a virus,1,adeno-associated virus,3
177,virus,1,human,3
178,evading,1,gynecologic cancer,3
179,strategies,1,ovarian,3
180,biotherapy,1,neurodegeneration,3
181,tnf,1,reverse genetics,3
182,rna pol ii promoter,1,oncogene,3
183,hydrodynamic delivery,1,chemotherapy,3
184,gene delivery,1,viral suppressor,3
185,therapeutic rnai,1,transplantation,3
186,virus infection,1,post-transcriptional gene silencing,3
187,virus-host interaction,1,anticancer therapeutics,3
188,cancer gene therapy,1,human cervical cancer,3
189,strategy,1,oncogenic viruses,3
190,polyglutamine,1,antithrombotic therapy,2
191,huntington disease,1,thrombosis,2
192,darpp-32,1,pharmacology,2
193,adeno-associated virus,1,synthase,2
194,resistance,1,hepatitis-c virus,2
195,escape,1,aptamer-sirna chimeras,2
196,dicer inhibition,1,multidrug resistant microorganism,2
197,human,1,nanoantibiotics,2
198,gynecologic cancer,1,pdx1,2
199,ovarian,1,pancreatic cancer,2
200,age-related macular degeneration,1,in vivo,2
201,ocular diseases,1,metastasis,2
202,respiratory diseases,1,non-hodgkins-lymphoma,2
203,neurodegeneration,1,toll-like receptor-3,2
204,reverse genetics,1,rna pol ii promoter,2
205,oncogene,1,hydrodynamic delivery,2
206,chemotherapy,1,virus infection,2
207,viral suppressor,1,virus-host interaction,2
208,transplantation,1,cancer gene therapy,2
209,blood-brain barrier,1,strategy,2
210,epidermal growth factor receptor,1,age-related macular degeneration,2
211,insulin receptor,1,ocular diseases,2
212,molecular oncology,1,respiratory diseases,2
213,post-transcriptional gene silencing,1,blood-brain barrier,2
214,anticancer therapeutics,1,epidermal growth factor receptor,2
215,human cervical cancer,1,insulin receptor,2
216,oncogenic viruses,1,"rna, small interfering (sirna)",2
217,"rna, small interfering (sirna)",1,molecular oncology,1
